Close menu

June 7th, 2021 | 11:06 CEST

QMines, BioNTech, Beyond Meat - Stock pearls with a lot of potential

  • Investments
Photo credits:

Commodity prices are rising, Corona is still a major theme and stock gambles, like AMC last week, are still working. As a resourceful investor, you have to do your research and ideally get an information edge over other investors. If you read a lot, you learn a lot and can often profit from it. Today we have picked out three stocks with a lot of potential - one from the commodities sector, another the Corona flagship and a chance on the next AMC.

time to read: 2 minutes | Author: Armin Schulz
ISIN: AU0000141533 , US09075V1026 , US08862E1091

Table of contents:

    QMines - Eagerly awaiting the update

    Recently listed Australian junior explorer QMines has reported the first results from its historic Mount Chalmers project. It has some high-grade copper-gold-silver deposits. 11 holes were drilled for 1,587m with up to 13.4% copper, 6.11 grams per tonne gold, and 31 grams per tonne silver.

    The Company has been working on reactivating Mount Chalmers for some time, evaluating historical drill data as the project had been dormant for 25 years. In February, the drill program started to confirm the historical data. CEO Andrew Sparke feels that Mount Chalmers has excellent development potential. Good results are expected to continue, leading to a resource update.

    QMines also aims to excel in sustainability and become Australia's first carbon-free copper and gold developer. The upcoming results are eagerly awaited. The share price rose by 60% when the first drill results were announced. It has now been sold off again, and the gap has almost been closed. If the upcoming results continue to show such good values, there is a chance of doubling.

    BioNTech - An industry leader with a product pipeline

    BioNTech is the most renowned vaccine manufacturer, made in Germany. For 2020, the Company could report total sales of USD 482 million. BioNTech is approved throughout Europe for all children 12 years and older. Last week, approvals were also reported in Switzerland and the United Kingdom. The clinical trial in adolescents between 12 and 15 years of age showed 100% protection against disease. Now national vaccination committees must decide whether to approve the vaccine.

    There is also good news for BioNTech in the patent dispute. The EU Commission favors compulsory licensing, which means BioNTech would allow other companies from poorer countries to produce the vaccine in exchange for money. That way, money would still flow into the Company's coffers, even if they stopped making it themselves. BioNTech is more than just the Corona vaccine, however. A total of 22 drugs are in development, and if Corona opened the door to other mRNA substances, there are still plenty of opportunities.

    There was a sell-off following the push by the US to remove patent protection. However, this has now been offset, and the stock has formed a new all-time high. Sales of around USD 10 billion are expected for 2021. Should the drugs in development prove useful, there is even more price fantasy here. Lots of potential, but just not immediately. One should wait for a setback to enter.

    Beyond Meat - Trend market and possible short squeeze

    Beyond Meat's quarterly figures were poor. Both sales and profits were missed. Restaurant sales were down as much as 34%, and retail sales were also down a whopping 40% year-on-year, growing 45%. In addition, inflation is taking its toll on the Company and profit margins are thinning as there is also more and more competition.

    Still, this should only be a short-term picture, as the trend toward healthy, sustainable eating continues to grow. Even though retail will not continue to grow as strongly in the long run, it is building a decent foundation. Sales of vegan meat products in Germany increased by nearly 100% in 2020. After Corona, restaurants will also increasingly turn to Beyond Meat products again.

    So why might Beyond Meat's stock be a stock with a lot of potential? For that, you should take a look at Reddit, where the stock is being hotly debated because it has a 25% short ratio. Like AMC recently, there could be a short squeeze here. The stock already jumped last week and Jim Cramer, a CNBC stock market commentator, is fueling the sentiment with tweets. Those not afraid of risk could bet on the next AMC with Beyond Meat.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.

    Der Autor

    Armin Schulz

    Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

    About the author

    Related comments:

    Commented by Juliane Zielonka on December 1st, 2022 | 10:44 CET

    Aspermont, Twitter, Apple - Strong numbers, strong visions and marketplace power

    • Digitization
    • Commodities
    • Investments

    The Australian media company for the commodities industry has presented its latest figures. The results are impressive, with total revenue up 17% YOY, among other things. This industry pioneer illustrates just how valuable access to high-quality information can be. Perhaps soon to disappear from the scene is Elon Musk's Twitter: Find out how strong its dependence on the App Store giant is and what impact Apple fees may have on its revenue model here.


    Commented by Fabian Lorenz on November 30th, 2022 | 13:31 CET

    Biotech stocks in focus: Morphosys, Evotec, Bayer, BioNxt Solutions

    • Biotechnology
    • Cancer
    • Investments

    Biotech stocks have struggled in 2022. In Germany, BioNTech has overtaken the previous heavyweights Morphosys and Evotec in record time. Morphosys shocked investors with data on its Alzheimer's hope. Analysts lowered their thumbs, and short-sellers discovered the stock for themselves. Evotec has been quiet this year. Analysts think the valuation is attractive, but meeting earnings guidance in the current year is not a given. BioNxt shares have jumped recently, and if the positive newsflow continues into 2023, a re-rating is possible. At Bayer, the pharmaceuticals division is also developing positively. Conclusion: investors should position themselves for the biotech year 2023.


    Commented by Stefan Feulner on November 29th, 2022 | 13:32 CET

    Nvidia, Meta Materials, SFC Energy - Strong signs

    • Technology
    • Investments
    • nanotechnology

    After turbulent months on the technology stock markets with high markdowns, a bottoming out is taking place across the board. While many companies are reporting better-than-expected figures, investors are also buying oversold companies whose quarterly figures were below analysts' consensus. Due to the still high fluctuation range, high trading profits can be expected.